[
    [
        {
            "time": "2019-04-22",
            "original_text": "爱尓眼科2019年度分配预案：拟10送3股派1.5元",
            "features": {
                "keywords": [
                    "爱尓眼科",
                    "分配预案",
                    "10送3股",
                    "派1.5元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "爱尓眼科2019年度分配预案：拟10送3股派1.5元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-04-22",
            "original_text": "格隆汇港股聚焦(4.22)︱中国联通一季度净利同比下降超一成远航港口一季度纯利预增逾四成",
            "features": {
                "keywords": [
                    "中国联通",
                    "一季度",
                    "净利",
                    "同比下降",
                    "远航港口",
                    "纯利预增"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "通信",
                    "港口"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(4.22)︱中国联通一季度净利同比下降超一成远航港口一季度纯利预增逾四成",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-04-22",
            "original_text": "复星医药(02196)发行总额不超过50亿元公司债券的注册申请获同意",
            "features": {
                "keywords": [
                    "复星医药",
                    "发行",
                    "公司债券",
                    "50亿元",
                    "注册申请",
                    "获同意"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "复星医药(02196)发行总额不超过50亿元公司债券的注册申请获同意",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-04-22",
            "original_text": "复星医药子公司匹伐他汀钙片通过仿制药一致性评价",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "匹伐他汀钙片",
                    "仿制药",
                    "一致性评价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "复星医药子公司匹伐他汀钙片通过仿制药一致性评价",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-04-22",
            "original_text": "北水动向(4.22)|北水净流入9.68亿 平安好医生(01833)获2.64亿增持 股价再破顶",
            "features": {
                "keywords": [
                    "北水",
                    "净流入",
                    "平安好医生",
                    "增持",
                    "股价再破顶"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "北水动向(4.22)|北水净流入9.68亿 平安好医生(01833)获2.64亿增持 股价再破顶",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-04-22",
            "original_text": "辉瑞和BioNTech开展新冠疫苗获批临床 后者系复星医药合作伙伴",
            "features": {
                "keywords": [
                    "辉瑞",
                    "BioNTech",
                    "新冠疫苗",
                    "临床",
                    "复星医药",
                    "合作伙伴"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "辉瑞和BioNTech开展新冠疫苗获批临床 后者系复星医药合作伙伴",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]